Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
about
Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.Up-regulation of FGFBP1 signaling contributes to miR-146a-induced angiogenesis in human umbilical vein endothelial cells.Regulation of cAMP Responsive Element Binding Protein 3-Like 1 (Creb3l1) Expression by Orphan Nuclear Receptor Nr4a1.CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy
P2860
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@ast
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@en
type
label
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@ast
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@en
prefLabel
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@ast
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@en
P2093
P2860
P1433
P1476
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
@en
P2093
Andrea Pavia-Jimenez
Bray Denard
Harris Naina
Noelle S Williams
Robert Collins
Weina Chen
P2860
P304
P356
10.1371/JOURNAL.PONE.0129233
P407
P577
2015-06-25T00:00:00Z